{"id":1479,"date":"2004-08-01T12:03:00","date_gmt":"2004-08-01T10:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/symptomatische-hypokalziaemien-nach-bisphosphonat-infusionen"},"modified":"2004-08-01T12:03:00","modified_gmt":"2004-08-01T10:03:00","slug":"symptomatische-hypokalziaemien-nach-bisphosphonat-infusionen","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/symptomatische-hypokalziaemien-nach-bisphosphonat-infusionen","title":{"rendered":"Symptomatische Hypokalzi\u00e4mien nach Bisphosphonat-Infusionen"},"content":{"rendered":"<p>R. Peter et al. aus Liverpool, U.K., berichten im Brit. Med. J. \u00fcber 4 Patienten, die wegen Hyperkalzi\u00e4mie (n = 3) oder wegen Schmerzen durch Knochenmetastasen (n = 1) Kurzinfusionen mit 4 mg Zoledrons\u00e4ure (Zometa\u00ae, n = 2) oder 60 bzw. 90 mg Pamidrons\u00e4ure (Aredia\u00ae, n = 2) erhalten hatten, und bei denen nach wenigen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>R. Peter et al. aus Liverpool, U.K., berichten im Brit. Med. J. \u00fcber 4 Patienten, die wegen Hyperkalzi\u00e4mie (n = 3) oder wegen Schmerzen durch Knochenmetastasen (n = 1) Kurzinfusionen mit 4 mg Zoledrons\u00e4ure (Zometa\u00ae, n = 2) oder 60 bzw. 90 mg Pamidrons\u00e4ure (Aredia\u00ae, n = 2) erhalten hatten, und bei denen nach wenigen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[145,3509,1616,1098,1097],"class_list":["post-1479","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-bisphosphonate","tag-hypokalziaemie","tag-pamidronsaeure","tag-zoledronat","tag-zoledronsaeure"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1479"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1479\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}